期刊文献+

参芪膜肾颗粒辨证治疗特发性膜性肾病随机平行对照研究

TCM Treatment of Idiopathic Membranous Nephropathy Randomized Controlled Study
下载PDF
导出
摘要 [目的]观察参芪膜肾颗粒辨证治疗特发性膜性肾病疗效。[方法]使用随机平行对照方法,将400例住院患者按随机数字表法分为两组。对照组200例洛汀新20mg/次,1次/d。潘生丁150mg/次,1次/d。胰激肽原酶360U/次,1次/d。高血脂加服立普妥10mg/次,1次/d。治疗组200例参芪膜肾颗粒。湿热较重加清热膜肾冲剂;肾气虚加固肾颗粒;肾阳虚加益肾颗粒;脾虚腹泻加补脾益肠丸;低蛋白血症或严重浮肿加黑料豆颗粒;严重水肿加黄芪注射液。连续治疗24周为1疗程。观测临床症状、生存率、肾功能(24h尿蛋白、血清肌酐)、血清白蛋白、不良反应。连续治疗1疗程,判定疗效。[结果]治疗组完全缓解86例,缓解83例,无效31例,总有效率84.50%,生存率93.00%。对照组完全缓解41例,缓解110例,无效49例,总有效率75.50%,生存率85.50%。治疗组疗效优于对照组(P<0.05)。[结论]参芪膜肾颗粒辨证治疗特发性膜性肾病,疗效较好,安全可靠,值得推广。 [Objective]Observe the traditional Chinese medicine program idiopathic membranous nephropathy effect.[Methods]Randomized controlled method,400 inpatients were randomly randomly divided into two groups.Control group of 200 patients with western medicine.Treatment group two hundred cases of Chinese medicine are brought about by Differential Treatment.Continuously for 24 weeks for a course of treatment,observation of clinical efficacy,adverse reactions.Continuous one course of treatment,to determine efficacy.[Results]The complete remission,86 cases to ease the 83 cases,31 cases ineffective,the total effective rate of 84.50%,93.00% survival rate.Control group,complete remission in 41 cases,to ease the 110 cases,49 cases ineffective,the total effective rate was 75.50%,the survival rate of 85.50%.The clinical efficacy of the treatment groupthan the control group(P< 0.05).[ Conclusion]TCM treatment of idiopathic membranous nephropathy,good effect,safe and reliable,worthy of promotion.
作者 张廷友
出处 《实用中医内科杂志》 2013年第2S期40-41,共2页 Journal of Practical Traditional Chinese Internal Medicine
关键词 特发性膜性肾病 参芪膜肾颗粒 清热膜肾冲剂 固肾颗粒 益肾颗粒 补脾益肠丸 黑料豆颗粒 黄芪注射液 Idiopathic membranous nephropathy The Shenqi film kidney particles The heat film renal granules Gushen particles Kidney particles Pill of Bupiyichang Black materials beans particles Astragalus injection TCM Random parallel control study
  • 相关文献

参考文献5

二级参考文献21

  • 1王成,娄探奇,彭晖,刘迅,陈珠江,唐骅,余学清.来氟米特联合泼尼松治疗难治性原发性肾病综合征的随机对照试验[J].中国新药与临床杂志,2006,25(12):889-892. 被引量:27
  • 2魏建冬,黎磊石,姚建.大黄治疗大鼠系膜增殖性肾炎的实验研究[J].中华内科杂志,1997,36(2):87-89. 被引量:64
  • 3Katafuchi R, Kiyoshi Y, Oh Y, et al. Glomererular score as a prognosticator in IgA nephropathy: its usefulness and limitation[J]. Cin Nephrol, 1998,49( 1 ):1-8.
  • 4Maisonneuve P, Agodoa L, Gellert R, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study[J]. Am J Kidney Dis, 2000, 35:157-165.
  • 5Cattran D. Management of membranous nephropathy: when and what for treatment [J]. J Am Soc Nephrol,2005, 16: 1188-1194.
  • 6Shiiki H, Saito T, Nishitani Y, et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephritic syndrome in Japan [J]. Kidney int,2004,65(4) :1400-1407.
  • 7Szeto CC, Leung CB, Lai FM ,et al. Tacrelimus in resistant primary membranous nephropathy-a report of 3 cases[ J]. Clin Nephrol,2003 ;59( 4 ) : 293-6.
  • 8Praga M, Barrio V ,Juarez GF, et al. Tacrolimus monotherapy in membranous nephropathy:a randomized controlled trial[J]. Kidney Int,2007,71 (9) :924-30.
  • 9孙广东,许钟镐,罗萍,苗里宁.他克莫司治疗特发性膜性肾病的临床疗效观察[J].中国老年学杂志,2008,28(5):469-471. 被引量:21
  • 10王艺萍,王素霞.成人特发性膜性肾病168例临床与病理分析[J].中国误诊学杂志,2008,8(31):7699-7700. 被引量:11

共引文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部